Home LiteratureArticle Details
PMID: 21200394 Published · ppublish English Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Review

Bone metastasis: mechanisms and therapeutic opportunities.

Nature reviews. Endocrinology ·Vol. 7 ·No. 4 ·2011-04-00 ·Pages 208-18

Suva LJ, Washam C, Nicholas RW, Griffin RJ

Abstract

The skeleton is one of the most common sites for metastatic cancer, and tumors arising from the breast or prostate possess an increased propensity to spread to this site. The growth of disseminated tumor cells in the skeleton requires tumor cells to inhabit the bone marrow, from which they stimulate local bone cell activity. Crosstalk between tumor cells and resident bone and bone marrow cells disrupts normal bone homeostasis, which leads to tumor growth in bone. The metastatic tumor cells have the ability to elicit responses that stimulate bone resorption, bone formation or both. The net result of these activities is profound skeletal destruction that can have dire consequences for patients. The molecular mechanisms that underlie these painful and often incurable consequences of tumor metastasis to bone are beginning to be recognized, and they represent promising new molecular targets for therapy.

MeSH Terms
Bone Neoplasms/drug therapy,metabolism,secondary Breast Neoplasms/complications,metabolism Female Humans Male Models, Biological Prostatic Neoplasms/complications,metabolism Signal Transduction
Authors & Affiliations
4 authors, click to expand affiliations / ORCID
Suva Larry J
Department of Orthopedic Surgery, Center for Orthopedic Research, Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, 4301 West Markham Street, Little Rock, AR 72205, USA. suvalarryj@uams.edu
Washam Charity
Nicholas Richard W
Griffin Robert J
References (124)
124 references, click to expand
  1. Biochemical and histological evidence that carcinoma of the prostate is associated with increased bone resorption.
    Eur J Surg Oncol. 1987 Feb;13(1):41-9 PMID: 3102281
  2. Platelet dysfunction and a high bone mass phenotype in a murine model of platelet-type von Willebrand disease.
    Am J Pathol. 2008 Feb;172(2):430-9 PMID: 18187573
  3. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma.
    N Engl J Med. 2003 Dec 25;349(26):2483-94 PMID: 14695408
  4. Pathogenesis of myeloma bone disease.
    Blood Cells Mol Dis. 2004 Mar-Apr;32(2):290-2 PMID: 15003820
  5. Therapeutic approaches to bone diseases.
    Science. 2000 Sep 1;289(5484):1508-14 PMID: 10968781
  6. De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent.
    Cancer Cell. 2005 May;7(5):411-23 PMID: 15894262
  7. Transforming growth factor beta affects osteoclast differentiation via direct and indirect actions.
    J Bone Miner Res. 2001 Oct;16(10):1787-94 PMID: 11585342
  8. A parathyroid hormone-related protein implicated in malignant hypercalcemia: cloning and expression.
    Science. 1987 Aug 21;237(4817):893-6 PMID: 3616618
  9. Pharmacologic inhibition of the TGF-beta type I receptor kinase has anabolic and anti-catabolic effects on bone.
    PLoS One. 2009;4(4):e5275 PMID: 19357790
  10. Platelets amplify inflammation in arthritis via collagen-dependent microparticle production.
    Science. 2010 Jan 29;327(5965):580-3 PMID: 20110505
  11. Enhanced paracrine FGF10 expression promotes formation of multifocal prostate adenocarcinoma and an increase in epithelial androgen receptor.
    Cancer Cell. 2007 Dec;12(6):572-85 PMID: 18068633
  12. The logic of TGFbeta signaling.
    FEBS Lett. 2006 May 22;580(12):2811-20 PMID: 16678165
  13. Markers of bone turnover for the management of patients with bone metastases from prostate cancer.
    Br J Cancer. 2000 Feb;82(4):858-64 PMID: 10732759
  14. Regulation of bone mass by mechanical loading: microarchitecture and genetics.
    Curr Osteoporos Rep. 2005 Jun;3(2):46-51 PMID: 16036101
  15. Heparin-binding growth factor gene expression and receptor characteristics in normal rat prostate and two transplantable rat prostate tumors.
    Cancer Res. 1989 May 1;49(9):2485-94 PMID: 2468410
  16. Distant metastases in head and neck cancer patients who achieved loco-regional control.
    Head Neck. 2000 Oct;22(7):680-6 PMID: 11002323
  17. Basic mechanisms responsible for osteolytic and osteoblastic bone metastases.
    Clin Cancer Res. 2006 Oct 15;12(20 Pt 2):6213s-6216s PMID: 17062703
  18. Expression of heparanase by primary breast tumors promotes bone resorption in the absence of detectable bone metastases.
    Cancer Res. 2005 Jul 1;65(13):5778-84 PMID: 15994953
  19. A local bone anabolic effect of rhFGF2-impregnated gelatin hydrogel by promoting cell proliferation and coordinating osteoblastic differentiation.
    Bone. 2009 Apr;44(4):699-707 PMID: 19166987
  20. Endothelin signaling in osteoblasts: global genome view and implication of the calcineurin/NFAT pathway.
    Mol Cancer Ther. 2007 Jan;6(1):253-61 PMID: 17237284
  21. Mechanisms of bone metastasis.
    N Engl J Med. 2004 Apr 15;350(16):1655-64 PMID: 15084698
  22. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study.
    J Clin Oncol. 2010 Dec 10;28(35):5132-9 PMID: 21060033
  23. Repression of multiple myeloma growth and preservation of bone with combined radiotherapy and anti-angiogenic agent.
    Radiat Res. 2010 Jun;173(6):809-17 PMID: 20518660
  24. Bone markers and their prognostic value in metastatic bone disease: clinical evidence and future directions.
    Cancer Treat Rev. 2008 Nov;34(7):629-39 PMID: 18579314
  25. Heparan sulfate proteoglycans and heparanase--partners in osteolytic tumor growth and metastasis.
    Matrix Biol. 2004 Oct;23(6):341-52 PMID: 15533755
  26. The detection of circulating breast cancer cells in blood.
    J Clin Pathol. 2004 Sep;57(9):903-11 PMID: 15333648
  27. Breast cancer metastasis to bone: it is not all about PTHrP.
    Clin Orthop Relat Res. 2003 Oct;(415 Suppl):S39-45 PMID: 14600591
  28. Denosumab in postmenopausal women with low bone mineral density.
    N Engl J Med. 2006 Feb 23;354(8):821-31 PMID: 16495394
  29. Advances in the biology of bone metastasis: how the skeleton affects tumor behavior.
    Bone. 2011 Jan;48(1):6-15 PMID: 20643235
  30. Inhibitor of DASH proteases affects expression of adhesion molecules in osteoclasts and reduces myeloma growth and bone disease.
    Br J Haematol. 2009 Jun;145(6):775-87 PMID: 19388929
  31. Bone morphogenetic protein 7 is expressed in prostate cancer metastases and its effects on prostate tumor cells depend on cell phenotype and the tumor microenvironment.
    Neoplasia. 2010 Feb;12(2):192-205 PMID: 20126477
  32. Influence of BMPs on the formation of osteoblastic lesions in metastatic prostate cancer.
    J Bone Miner Res. 2005 Dec;20(12):2189-99 PMID: 16294272
  33. Histopathological assessment of prostate cancer bone osteoblastic metastases.
    J Urol. 2008 Sep;180(3):1154-60 PMID: 18639279
  34. Clonal selection of metastasis within the life history of a tumor.
    Cancer Res. 2007 Dec 15;67(24):11471-5 PMID: 18089772
  35. The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited.
    Nat Rev Cancer. 2003 Jun;3(6):453-8 PMID: 12778135
  36. Mechanisms of TGF-beta signaling from cell membrane to the nucleus.
    Cell. 2003 Jun 13;113(6):685-700 PMID: 12809600
  37. Characterization of the glycosylation profile of the human breast cancer cell line, MDA-231, and a bone colonizing variant.
    Int J Oncol. 2006 May;28(5):1173-83 PMID: 16596233
  38. Immune cells as mediators of solid tumor metastasis.
    Cancer Metastasis Rev. 2008 Mar;27(1):11-8 PMID: 18066650
  39. Fibroblast growth factors in development and cancer: insights from the mammary and prostate glands.
    Curr Drug Targets. 2009 Jul;10(7):632-44 PMID: 19601767
  40. Tumor growth need not be driven by rare cancer stem cells.
    Science. 2007 Jul 20;317(5836):337 PMID: 17641192
  41. Endogenous bone morphogenetic protein-7 controls the motility of prostate cancer cells through regulation of bone morphogenetic protein antagonists.
    J Urol. 2007 Sep;178(3 Pt 1):1086-91 PMID: 17644136
  42. Role of endothelin-1 in osteoblastic bone metastases.
    Cancer. 2003 Feb 1;97(3 Suppl):779-84 PMID: 12548575
  43. Platelet-derived lysophosphatidic acid supports the progression of osteolytic bone metastases in breast cancer.
    J Clin Invest. 2004 Dec;114(12):1714-25 PMID: 15599396
  44. Beyond tumorigenesis: cancer stem cells in metastasis.
    Cell Res. 2007 Jan;17(1):3-14 PMID: 17179981
  45. Inducible FGFR-1 activation leads to irreversible prostate adenocarcinoma and an epithelial-to-mesenchymal transition.
    Cancer Cell. 2007 Dec;12(6):559-71 PMID: 18068632
  46. Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases.
    J Clin Oncol. 2007 Oct 1;25(28):4431-7 PMID: 17785705
  47. Overview of resistance to systemic therapy in patients with breast cancer.
    Adv Exp Med Biol. 2007;608:1-22 PMID: 17993229
  48. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation.
    Cell. 1998 Apr 17;93(2):165-76 PMID: 9568710
  49. The distribution of secondary growths in cancer of the breast. 1889.
    Cancer Metastasis Rev. 1989 Aug;8(2):98-101 PMID: 2673568
  50. Roles of a prostaglandin E-type receptor, EP3, in upregulation of matrix metalloproteinase-9 and vascular endothelial growth factor during enhancement of tumor metastasis.
    Cancer Sci. 2009 Dec;100(12):2318-24 PMID: 19799610
  51. A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer.
    Clin Cancer Res. 2006 Feb 15;12(4):1221-8 PMID: 16489077
  52. Manipulating the environment of cancer cells in bone: a novel therapeutic approach.
    J Clin Invest. 2002 Nov;110(10):1399-401 PMID: 12438435
  53. Mechanisms of bone metastases of breast cancer.
    Endocr Relat Cancer. 2009 Sep;16(3):703-13 PMID: 19443538
  54. Dynamic heterogeneity: rapid generation of metastatic variants in mouse B16 melanoma cells.
    Science. 1984 Jun 1;224(4652):998-1001 PMID: 6719130
  55. RANKL-dependent and RANKL-independent mechanisms of macrophage-osteoclast differentiation in breast cancer.
    Breast Cancer Res Treat. 2007 Sep;105(1):7-16 PMID: 17151927
  56. Breast cancer metastasis: markers and models.
    Nat Rev Cancer. 2005 Aug;5(8):591-602 PMID: 16056258
  57. Mechanism of bone metastasis: the role of osteoprotegerin and of the host-tissue microenvironment-related survival factors.
    Cancer Lett. 2009 Sep 28;283(1):10-9 PMID: 19201081
  58. An open-label, phase 2 trial of denosumab in the treatment of relapsed or plateau-phase multiple myeloma.
    Am J Hematol. 2009 Oct;84(10):650-6 PMID: 19714603
  59. Metastasizing potentials of mouse mammary tumors and their metastases.
    Int J Cancer. 1988 Jun 15;41(6):855-8 PMID: 3372061
  60. Targeting factors involved in bone remodeling as treatment strategies in prostate cancer bone metastasis.
    Clin Cancer Res. 2006 Oct 15;12(20 Pt 2):6285s-6290s PMID: 17062715
  61. Physiological actions and clinical applications of transforming growth factor-beta (TGF-beta).
    Growth Factors. 1993;8(1):1-9 PMID: 8448037
  62. Clinical importance and therapeutic implications of the pivotal CXCL12-CXCR4 (chemokine ligand-receptor) interaction in cancer cell migration.
    Tumour Biol. 2007;28(3):123-31 PMID: 17510563
  63. Metastases from malignant melanoma to the axial skeleton: a CT study of frequency and appearance.
    AJR Am J Roentgenol. 1990 Jul;155(1):109-12 PMID: 2112830
  64. New insights into the role of T cells in the vicious cycle of bone metastases.
    Curr Opin Rheumatol. 2006 Jul;18(4):396-404 PMID: 16763461
  65. Human amniotic tumor that induces new bone formation in vivo produces growth-regulatory activity in vitro for osteoblasts identified as an extended form of basic fibroblast growth factor.
    Cancer Res. 1996 Feb 1;56(3):633-6 PMID: 8564983
  66. Novel bone-targeted strategies in oncology.
    Clin Cancer Res. 2010 Aug 15;16(16):4084-93 PMID: 20643782
  67. Conclusion: Bone markers in metastatic bone disease.
    Cancer Treat Rev. 2006;32 Suppl 1:27-8 PMID: 16680836
  68. Bone morphogenetic protein signaling in prostate cancer cell lines.
    J Cell Biochem. 2004 Jan 1;91(1):151-60 PMID: 14689587
  69. Endocrine therapy plus zoledronic acid in premenopausal breast cancer.
    N Engl J Med. 2009 Feb 12;360(7):679-91 PMID: 19213681
  70. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL.
    Proc Natl Acad Sci U S A. 1998 Mar 31;95(7):3597-602 PMID: 9520411
  71. Parathyroid hormone-related protein localization in breast cancers predict improved prognosis.
    Cancer Res. 2006 Feb 15;66(4):2250-6 PMID: 16489028
  72. Heparin binding affinity of rat prostatic growth factor in normal and cancerous prostates: partial purification and characterization of rat prostatic growth factor in the Dunning tumor.
    Cancer Res. 1987 Jan 1;47(1):188-92 PMID: 3791206
  73. The biology of cancer invasion and metastasis.
    Adv Cancer Res. 1978;28:149-250 PMID: 360795
  74. Interleukin-6 and interleukin-11 support human osteoclast formation by a RANKL-independent mechanism.
    Bone. 2003 Jan;32(1):1-7 PMID: 12584029
  75. The critical role of the bone microenvironment in cancer metastases.
    Mol Cell Endocrinol. 2009 Oct 30;310(1-2):71-81 PMID: 19616059
  76. Extended efficacy and safety of denosumab in breast cancer patients with bone metastases not receiving prior bisphosphonate therapy.
    Clin Cancer Res. 2008 Oct 15;14(20):6690-6 PMID: 18927312
  77. The role of Wnts in bone metastases.
    Cancer Metastasis Rev. 2006 Dec;25(4):551-8 PMID: 17160558
  78. Adaptation versus selection: the origins of metastatic behavior.
    Cancer Res. 2007 Dec 15;67(24):11476-9; discussion 11479-80 PMID: 18089773
  79. Adjuvant bisphosphonates in breast cancer: are we witnessing the emergence of a new therapeutic strategy?
    Eur J Cancer. 2009 Jul;45(11):1909-15 PMID: 19447606
  80. Quantitative bone histomorphometry in humoral hypercalcemia of malignancy: uncoupling of bone cell activity.
    J Clin Endocrinol Metab. 1982 Aug;55(2):219-27 PMID: 7085851
  81. Skeletal complications of malignancy.
    Cancer. 1997 Oct 15;80(8 Suppl):1588-94 PMID: 9362426
  82. Inflammation and cancer.
    Nature. 2002 Dec 19-26;420(6917):860-7 PMID: 12490959
  83. Clinical features of metastatic bone disease and risk of skeletal morbidity.
    Clin Cancer Res. 2006 Oct 15;12(20 Pt 2):6243s-6249s PMID: 17062708
  84. LNCaP progression model of human prostate cancer: androgen-independence and osseous metastasis.
    Prostate. 2000 Jul 1;44(2):91-103 Jul 1;44(2) PMID: 10881018
  85. Scanning electron microscopy in bone pathology: review of methods, potential and applications.
    Scan Electron Microsc. 1986;(Pt 4):1537-54 PMID: 3544196
  86. Adjuvant bisphosphonates in breast cancer: the ABCSG-12 study.
    Curr Osteoporos Rep. 2010 Jun;8(2):57-9 PMID: 20425611
  87. A causal role for endothelin-1 in the pathogenesis of osteoblastic bone metastases.
    Proc Natl Acad Sci U S A. 2003 Sep 16;100(19):10954-9 PMID: 12941866
  88. Cancer metastasis facilitated by developmental pathways: Sonic hedgehog, Notch, and bone morphogenic proteins.
    J Cell Biochem. 2007 Nov 1;102(4):829-39 PMID: 17914743
  89. Interleukin-7 stimulates osteoclast formation by up-regulating the T-cell production of soluble osteoclastogenic cytokines.
    Blood. 2000 Sep 1;96(5):1873-8 PMID: 10961889
  90. Biochemical markers of bone turnover in patients with metastatic bone disease.
    Clin Chem. 1995 Oct;41(10):1489-94 PMID: 7586522
  91. Proteolysis of latent transforming growth factor-beta (TGF-beta )-binding protein-1 by osteoclasts. A cellular mechanism for release of TGF-beta from bone matrix.
    J Biol Chem. 2002 Jun 14;277(24):21352-60 PMID: 11929865
  92. A reassessment of bone scintigraphy and commonly tested pretreatment biochemical parameters in newly diagnosed osteosarcoma.
    J Cancer Res Clin Oncol. 2002 Jul;128(7):393-9 PMID: 12136254
  93. The hallmarks of cancer.
    Cell. 2000 Jan 7;100(1):57-70 PMID: 10647931
  94. Expression of bone morphogenetic protein messenger RNAs by normal rat and human prostate and prostate cancer cells.
    Prostate. 1994 Apr;24(4):204-11 PMID: 8146069
  95. Systemic administration of acidic fibroblast growth factor (FGF-1) prevents bone loss and increases new bone formation in ovariectomized rats.
    J Bone Miner Res. 1999 Jun;14(6):953-9 PMID: 10352104
  96. Activin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone disease.
    Proc Natl Acad Sci U S A. 2010 Mar 16;107(11):5124-9 PMID: 20194748
  97. Stromal cell derived factor-1: its influence on invasiveness and migration of breast cancer cells in vitro, and its association with prognosis and survival in human breast cancer.
    Breast Cancer Res. 2005;7(4):R402-10 PMID: 15987445
  98. Platelet glycoprotein Ib alpha supports experimental lung metastasis.
    Proc Natl Acad Sci U S A. 2007 May 22;104(21):9024-8 PMID: 17494758
  99. Effects of the bisphosphonate olpadronate in patients with carcinoma of the prostate metastatic to the skeleton.
    Bone. 1998 Apr;22(4):403-8 PMID: 9556142
  100. A novel model of bone-metastatic prostate cancer in immunocompetent mice.
    Prostate. 2009 Nov 1;69(15):1613-23 PMID: 19585491
  101. Tumor-derived interleukin-8 stimulates osteolysis independent of the receptor activator of nuclear factor-kappaB ligand pathway.
    Cancer Res. 2005 Dec 1;65(23):11001-9 PMID: 16322249
  102. Prostate cancer cells promote osteoblastic bone metastases through Wnts.
    Cancer Res. 2005 Sep 1;65(17):7554-60 PMID: 16140917
  103. Metastasis to bone: causes, consequences and therapeutic opportunities.
    Nat Rev Cancer. 2002 Aug;2(8):584-93 PMID: 12154351
  104. New bone formation and osteolysis by a metastatic, highly invasive canine prostate carcinoma xenograft.
    Prostate. 2006 Aug 1;66(11):1213-22 PMID: 16683269
  105. Angiogenesis in the bone marrow of patients with breast cancer.
    Clin Cancer Res. 2005 Aug 1;11(15):5396-400 PMID: 16061853
  106. RANK ligand as a therapeutic target for bone metastases and multiple myeloma.
    Cancer Treat Rev. 2008 Feb;34(1):92-101 PMID: 17964729
  107. Histomorphometric analysis of sclerotic bone metastases from prostatic carcinoma special reference to osteomalacia.
    Cancer. 1983 Mar 1;51(5):918-24 PMID: 6681595
  108. Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis.
    J Clin Invest. 1996 Oct 1;98(7):1544-9 PMID: 8833902
  109. Regulation of osteoblastogenesis and bone mass by Wnt10b.
    Proc Natl Acad Sci U S A. 2005 Mar 1;102(9):3324-9 PMID: 15728361
  110. Dickkopf homolog 1 mediates endothelin-1-stimulated new bone formation.
    Mol Endocrinol. 2007 Feb;21(2):486-98 PMID: 17068196
  111. The pathogenesis of cancer metastasis.
    Nature. 1980 Jan 10;283(5743):139-46 PMID: 6985715
  112. In vivo stimulation of endosteal bone formation by basic fibroblast growth factor in rats.
    Growth Factors. 1993;9(1):73-80 PMID: 7688520
  113. Tumor-derived platelet-derived growth factor-BB plays a critical role in osteosclerotic bone metastasis in an animal model of human breast cancer.
    Cancer Res. 2002 Feb 1;62(3):917-23 PMID: 11830552
  114. The bone microenvironment in metastasis; what is special about bone?
    Cancer Metastasis Rev. 2008 Mar;27(1):41-55 PMID: 18071636
  115. The syndecan-1 heparan sulfate proteoglycan is a viable target for myeloma therapy.
    Blood. 2007 Sep 15;110(6):2041-8 PMID: 17536013
  116. Monocyte chemotactic protein-1 mediates prostate cancer-induced bone resorption.
    Cancer Res. 2007 Apr 15;67(8):3646-53 PMID: 17440076
  117. Tumor-derived syndecan-1 mediates distal cross-talk with bone that enhances osteoclastogenesis.
    J Bone Miner Res. 2010 Jun;25(6):1295-304 PMID: 20200931
  118. Localization of parathyroid hormone-related protein in breast cancer metastases: increased incidence in bone compared with other sites.
    Cancer Res. 1991 Jun 1;51(11):3059-61 PMID: 2032246
  119. Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates.
    J Clin Oncol. 2009 Apr 1;27(10):1564-71 PMID: 19237632
  120. The role of fibroblast growth factors and their receptors in prostate cancer.
    Endocr Relat Cancer. 2004 Dec;11(4):709-24 PMID: 15613447
  121. Identification and characterization of endothelin receptors on rat osteoblastic osteosarcoma cells: down-regulation by 1,25-dihydroxy-vitamin D3.
    Mol Pharmacol. 1995 Feb;47(2):266-71 PMID: 7870034
  122. Immunohistochemical localization of parathyroid hormone-related protein in human breast cancer.
    Cancer Res. 1990 Dec 1;50(23):7710-6 PMID: 2253214
  123. Immunochemical characterization of circulating parathyroid hormone-related protein in patients with humoral hypercalcemia of cancer.
    N Engl J Med. 1990 Apr 19;322(16):1106-12 PMID: 2320080
  124. Expression of bone morphogenetic protein receptors type-IA, -IB and -II correlates with tumor grade in human prostate cancer tissues.
    Cancer Res. 2000 Jun 1;60(11):2840-4 PMID: 10850425
Article Info
Journal
Nature reviews. Endocrinology
Abbr.
Nat Rev Endocrinol
ISSN
1759-5037
DOI
10.1038/nrendo.2010.227
Email
suvalarryj@uams.edu
Published
2011-04-00
Epub
2011-00-04
Pages
208-18
Language
English
Region
England
NLM ID
101500078
PMCID
PMC3134309
Subset
IM
Grants
NCI NIH HHS · R01 CA107160 · United States
NCI NIH HHS · R01 CA107160-05 · United States
NCI NIH HHS · 5R01CA107160 · United States
External Links
PubMed source DOI: 10.1038/nrendo.2010.227 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2